Literature DB >> 29360137

cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.

Elizabeth Brunt1, Shinichi Aishima2, Pierre-Alain Clavien3, Kathryn Fowler4, Zachary Goodman5, Gregory Gores6, Annette Gouw7, Alex Kagen8, David Klimstra9, Mina Komuta10, Fukuo Kondo11, Rebecca Miksad12, Masayuki Nakano13, Yasuni Nakanuma14, Irene Ng15, Valerie Paradis16, Young Nyun Park17, Alberto Quaglia18, Massimo Roncalli19, Tania Roskams20, Michiie Sakamoto21, Romil Saxena22, Christine Sempoux23, Claude Sirlin24, Ashley Stueck25, Swan Thung26, W M S Tsui27, Xin-Wei Wang28, Aileen Wee29, Hirohisa Yano30, Matthew Yeh31, Yoh Zen32, Jessica Zucman-Rossi33, Neil Theise34.   

Abstract

Primary liver carcinomas with both hepatocytic and cholangiocytic differentiation have been referred to as "combined (or mixed) hepatocellular-cholangiocarcinoma." These tumors, although described over 100 years ago, have attracted greater attention recently because of interest in possible stem cell origin and perhaps because of greater frequency and clinical recognition. Currently, because of a lack of common terminology in the literature, effective treatment and predictable outcome data have been challenging to accrue. This article represents a consensus document from an international community of pathologists, radiologists, and clinicians who have studied and reported on these tumors and recommends a working terminology for diagnostic and research approaches for further study and evaluation.
CONCLUSION: It is recommended that diagnosis is based on routine histopathology with hematoxylin and eosin (H&E); immunostains are supportive, but not essential for diagnosis. (Hepatology 2018;68:113-126).
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2018        PMID: 29360137      PMCID: PMC6340292          DOI: 10.1002/hep.29789

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  54 in total

1.  Cholangiolocellular carcinoma of the liver.

Authors:  P E STEINER; J HIGGINSON
Journal:  Cancer       Date:  1959 Jul-Aug       Impact factor: 6.860

2.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

3.  Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.

Authors:  Dominique Cazals-Hatem; Sandra Rebouissou; Paulette Bioulac-Sage; Olivier Bluteau; Hélène Blanché; Dominique Franco; Geneviève Monges; Jacques Belghiti; Antonio Sa Cunha; Pierre Laurent-Puig; Claude Degott; Jessica Zucman-Rossi
Journal:  J Hepatol       Date:  2004-08       Impact factor: 25.083

4.  Detection of combined hepatocellular and cholangiocarcinomas on enhanced CT: comparison with histologic findings.

Authors:  Akihiro Nishie; Kengo Yoshimitsu; Yoshiki Asayama; Hiroyuki Irie; Hitoshi Aibe; Tsuyoshi Tajima; Kenji Shinozaki; Tomohiro Nakayama; Daisuke Kakihara; Mitsuo Shimada; Shin-Ichi Aishima; Kisaku Yoshida; Hiroshi Honda
Journal:  AJR Am J Roentgenol       Date:  2005-04       Impact factor: 3.959

5.  Hepatocellular-cholangiocarcinoma: helical computed tomography findings in 30 patients.

Authors:  Osama Ebied; Michael P Federle; Arye Blachar; Giuseppe Brancatelli; Luigi Grazioli; Dominique Cazals-Hatem; Federica Dondero; Valérie Vilgrain
Journal:  J Comput Assist Tomogr       Date:  2003 Mar-Apr       Impact factor: 1.826

6.  Genetic classification of combined hepatocellular-cholangiocarcinoma.

Authors:  H Fujii; X G Zhu; T Matsumoto; M Inagaki; Y Tokusashi; N Miyokawa; T Fukusato; T Uekusa; T Takagaki; N Kadowaki; T Shirai
Journal:  Hum Pathol       Date:  2000-09       Impact factor: 3.466

7.  Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors.

Authors:  William R Jarnagin; Sharon Weber; Satish K Tickoo; Jonathan B Koea; Sam Obiekwe; Yuman Fong; Ronald P DeMatteo; Leslie H Blumgart; David Klimstra
Journal:  Cancer       Date:  2002-04-01       Impact factor: 6.860

8.  Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence.

Authors:  Takahiro Uenishi; Shoji Kubo; Takatsugu Yamamoto; Taichi Shuto; Masao Ogawa; Hiromu Tanaka; Shogo Tanaka; Kenji Kaneda; Kazuhiro Hirohashi
Journal:  Cancer Sci       Date:  2003-10       Impact factor: 6.716

9.  Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype.

Authors:  Haeryoung Kim; Chanil Park; Kwang-Hyup Han; Jinsub Choi; Young Bae Kim; Ja Kyung Kim; Young Nyun Park
Journal:  J Hepatol       Date:  2004-02       Impact factor: 25.083

10.  Hepatic 'stem cell' malignancies in adults: four cases.

Authors:  N D Theise; J L Yao; K Harada; P Hytiroglou; B Portmann; S N Thung; W Tsui; H Ohta; Y Nakanuma
Journal:  Histopathology       Date:  2003-09       Impact factor: 5.087

View more
  67 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 2.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

Review 3.  [Indications for transplantation and bridging procedures for primary hepatobiliary malignancies].

Authors:  J Mittler; S Heinrich; H Lang
Journal:  Chirurg       Date:  2018-11       Impact factor: 0.955

4.  How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?

Authors:  Hong Seon Lee; Myeong-Jin Kim; Chansik An
Journal:  Eur Radiol       Date:  2018-12-14       Impact factor: 5.315

5.  A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery.

Authors:  Feng Zhang; Keshu Hu; Bei Tang; Mengxin Tian; Shenxin Lu; Jia Yuan; Miao Li; Rongxin Chen; Zhenggang Ren; Yinghong Shi; Xin Yin
Journal:  J Gastrointest Surg       Date:  2020-04-29       Impact factor: 3.452

6.  Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.

Authors:  Daniel R Ludwig; Tyler J Fraum; Roberto Cannella; David H Ballard; Richard Tsai; Muhammad Naeem; Maverick LeBlanc; Amber Salter; Allan Tsung; Anup S Shetty; Amir A Borhani; Alessandro Furlan; Kathryn J Fowler
Journal:  Abdom Radiol (NY)       Date:  2019-06

Review 7.  Problematic lesions in cirrhotic liver mimicking hepatocellular carcinoma.

Authors:  Myeong-Jin Kim; Sunyoung Lee; Chansik An
Journal:  Eur Radiol       Date:  2019-02-20       Impact factor: 5.315

Review 8.  Tumour evolution in hepatocellular carcinoma.

Authors:  Amanda J Craig; Johann von Felden; Teresa Garcia-Lezana; Samantha Sarcognato; Augusto Villanueva
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-12-02       Impact factor: 46.802

Review 9.  The cellular origins of cancer with particular reference to the gastrointestinal tract.

Authors:  Malcolm R Alison
Journal:  Int J Exp Pathol       Date:  2020-08-14       Impact factor: 1.925

10.  Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.

Authors:  Tyler J Fraum; Roberto Cannella; Daniel R Ludwig; Richard Tsai; Muhammad Naeem; Maverick LeBlanc; Amber Salter; Allan Tsung; Anup S Shetty; Amir A Borhani; Alessandro Furlan; Kathryn J Fowler
Journal:  Eur Radiol       Date:  2019-10-25       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.